| Literature DB >> 30691372 |
Donna E Stewart1,2,3,4, Simone N Vigod1,5.
Abstract
Postpartum depression (PPD) is common, disabling, and treatable. The strongest risk factor is a history of mood or anxiety disorder, especially having active symptoms during pregnancy. As PPD is one of the most common complications of childbirth, it is vital to identify best treatments for optimal maternal, infant, and family outcomes. New understanding of PPD pathophysiology and emerging therapeutics offer the potential for new ways to add to current medications, somatic treatments, and evidence-based psychotherapy. The benefits and potential harms of treatment, including during breastfeeding, are presented.Entities:
Keywords: allopregnanolone; emerging therapies; genetic aspects; pathophysiology; postpartum depression
Mesh:
Substances:
Year: 2019 PMID: 30691372 DOI: 10.1146/annurev-med-041217-011106
Source DB: PubMed Journal: Annu Rev Med ISSN: 0066-4219 Impact factor: 13.739